Massachusetts Lawmakers Prioritize Health Policy
Katherine O'Malley
August 12, 2026
Massachusetts lawmakers made health policy their central focus of the 2025-2026 legislative session.
Massachusetts lawmakers made health policy their central focus of the 2025-2026 legislative session.
Massachusetts lawmakers made health policy their central focus of the 2025-2026 legislative session.
When anyone proposes reducing prescription drug prices — as Hillary Rodham Clinton and Bernie Sanders recently have — the most commonly heard criticism is that it would squelch innovation.
The exchanges are hurting. Uwe Reinhardt, among others, thinks the individual mandate isn’t stiff enough and that we’re too wimpy about its enforcement. Adrianna, among
Via Academia Obscura (click to enlarge … a little): @afrakt
6 Things That Happened in Health Policy This Week is produced by a mix of research assistants from the Healthcare Quality & Outcomes (HQO) Initiative
Most people, in general, would like to reduce the incidence of teen pregnancy. Yes, it’s at an all-time low here in the US, but that
The following originally appeared on The Upshot (copyright 2016, The New York Times Company). Three times in the last two weeks, people — a patient, a colleague
I spend a fair amount of time talking about how social determinants of health come into play, with respect to health care outcomes. I also
It’s been gratifying to watch the world suddenly coalesce around the idea that EpiPens are ridiculously expensive. The next step is, of course, figuring out
As I said in my first post in this series, the Orphan Drug Act of 1983 sure seems like it worked. Over the past few
Here’s what I told the USC Annenberg School of Journalism, and its newsletter included it today: Politico Pulse is very useful for the inside-the-beltway perspective. Pulse
My new AcademyHealth post provides an update on how ACA Marketplaces help (or don’t help) consumers select plans. If you’ve ever tried to select a
This is an email dialogue I had with Dan Diamond of POLITICO about conflicts of interest in journalism, think tanks, and universities. He’s one of